Elanco Projects 10% EPS Growth on Strong 2025 Performance

Edgen Stock·Feb 24 2026, 11:37

Share to

Share to

Copy link

Key Takeaways

Elanco Animal Health announced robust financial results for 2025 and provided an optimistic outlook for 2026, signaling strong operational momentum and success in its innovation pipeline. The company's performance points to continued growth in the animal health sector, driven by new product launches and expanding revenue.

Strong 2026 Outlook: The company forecasts 2026 adjusted EPS between $1.00 and $1.06, representing a 10% increase at the midpoint, with revenues projected at $4.95 billion to $5.02 billion.
Full-Year Growth: For the full year 2025, Elanco reported a 6% increase in revenue to $4.715 billion and an adjusted EPS of $0.94.
Innovation Success: Elanco exceeded its 2025 innovation revenue goal with $892 million and raised its 2026 target to $1.15 billion after delivering all six of its potential blockbuster products.

Elanco Forecasts 10% Adjusted EPS Growth for 2026

Elanco Animal Health issued strong financial guidance for the full year 2026, projecting significant growth based on its successful innovation strategy. The company anticipates revenue to land between $4.950 billion and $5.020 billion, which translates to organic constant currency growth of 4% to 6%. More notably for investors, adjusted earnings per share are forecasted to be in the range of $1.00 to $1.06, a 10% increase at the midpoint from 2025 levels.

This outlook is supported by a higher innovation revenue target, which has been raised to $1.15 billion for 2026. The company also aims to strengthen its balance sheet, targeting a year-end net leverage ratio between 3.1x and 3.3x adjusted EBITDA, an improvement from the 3.6x ratio at the end of 2025.

Full-Year 2025 Revenue Grew 6% to $4.7 Billion

The optimistic 2026 forecast is built upon a solid performance in 2025. Elanco reported full-year revenue of $4.715 billion, a 6% increase on a reported basis and a 7% rise in organic constant currency. The company's focus on new products paid off, delivering $892 million in innovation revenue and successfully launching all of its 'Big 6' potential blockbuster products by year-end, including the Befrena approval in the fourth quarter. Full-year 2025 adjusted EBITDA reached $901 million, with an adjusted EPS of $0.94.

Fourth-Quarter Revenue Climbed 12% to $1.14 Billion

Closing out the year, Elanco's fourth-quarter results demonstrated accelerating momentum. The company posted revenue of $1.144 billion for the quarter ending December 2025, a 12% increase from the prior year. On an adjusted basis, net income stood at $64 million, resulting in an adjusted EPS of $0.13. This performance was underpinned by an adjusted EBITDA of $189 million, representing a margin of 16.7%. While the company reported a net loss of $276 million for the quarter on a GAAP basis, the adjusted figures highlight underlying operational strength that supports its positive forward guidance.